Abstract
Human ovarian cancer, the leading cause of death from gynecologic malignancy, tends to remain localized to the peritoneal cavity until late in the disease. In established disease, ascitic fluid accumulates in the peritoneal cavity. We have previously demonstrated that this ascitic fluid is a potent source of in vitro mitogenic activity including at least one unique growth factor. We now report that the human ovarian adenocarcinoma line, HEY, can be induced to grow intraperitoneally in immunodeficient nude mice in the presence (23/28 mice), but not absence (0/21 mice) of ascitic fluid from ovarian cancer patients. Ascitic fluid from patients with benign disease did not have similar effects on intraperitoneal growth of HEY cells (1/15 mice). Once tumors were established by injections of exogenous ascitic fluid, they could progress in the absence of additional injections of ascitic fluid. The mice eventually developed ascitic fluid which contained potent growth factor activity, suggesting that the tumors eventually produced autologous growth factors. This nude mouse model provides a system to study the action of ovarian cancer growth factors on tumor growth in vivo and to evaluate preclinically, therapeutic approaches designed to counteract the activity of these growth factors.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baumal R., Law J., Buick R. N., Kahn H., Yeger H., Sheldon K., Colgan T., Marks A. Monoclonal antibodies to an epithelial ovarian adenocarcinoma: distinctive reactivity with xenografts of the original tumor and a cultured cell line. Cancer Res. 1986 Aug;46(8):3994–4000. [PubMed] [Google Scholar]
- Buick R. N., Pullano R., Trent J. M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res. 1985 Aug;45(8):3668–3676. [PubMed] [Google Scholar]
- Lotze M. T., Matory Y. L., Ettinghausen S. E., Rayner A. A., Sharrow S. O., Seipp C. A., Custer M. C., Rosenberg S. A. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985 Oct;135(4):2865–2875. [PubMed] [Google Scholar]
- Mills G. B., May C., McGill M., Roifman C. M., Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 1988 Mar 1;48(5):1066–1071. [PubMed] [Google Scholar]
- Richardson G. S., Scully R. E., Nikrui N., Nelson J. H., Jr Common epithelial cancer of the ovary (2). N Engl J Med. 1985 Feb 14;312(7):415–424. doi: 10.1056/NEJM198502143120706. [DOI] [PubMed] [Google Scholar]
- Richardson G. S., Scully R. E., Nikrui N., Nelson J. H., Jr Common epithelial cancer of the ovary (2). N Engl J Med. 1985 Feb 21;312(8):474–483. doi: 10.1056/NEJM198502213120804. [DOI] [PubMed] [Google Scholar]
- Shaw P., Buckman R., Law J., Baumal R., Marks A. Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies. Tumour Biol. 1988;9(2-3):101–109. doi: 10.1159/000217550. [DOI] [PubMed] [Google Scholar]
- Sheldon K., Marks A., Baumal R. Characterization of binding of four monoclonal antibodies to the human ovarian adenocarcinoma cell line HEY. Biochem Cell Biol. 1987 May;65(5):423–428. doi: 10.1139/o87-054. [DOI] [PubMed] [Google Scholar]
- Sporn M. B., Roberts A. B. Autocrine growth factors and cancer. 1985 Feb 28-Mar 6Nature. 313(6005):745–747. doi: 10.1038/313745a0. [DOI] [PubMed] [Google Scholar]
- Varmus H. E. The molecular genetics of cellular oncogenes. Annu Rev Genet. 1984;18:553–612. doi: 10.1146/annurev.ge.18.120184.003005. [DOI] [PubMed] [Google Scholar]